Neuroscientist With Research Program Joins Biotech’s SAB

Source: Streetwise Reports   01/29/2022

ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program.

Dr. Cheryl Wellington’s experience in blood-based biomarker tests for
neurological diseases is significant, ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) noted in a news release.

Measuring biomarkers, such as neurofilament light chain, or NfL; phosphorylated tau protein, or P-tau; and glial fibrillary acidic protein, or GAP, via blood sample is more ideal than doing so through cerebrospinal fluid.

The process is noninvasive and low risk in terms of complications. Fluid extraction is easy, allowing for multiple draws.

“These advantages make blood-based biomarkers ideal tools in Alzheimer’s disease clinical trials to assist in diagnosis and monitoring of patient progress on therapy,” the release indicated.

Disclosures:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences Inc. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.